Agreement with Ebtec Establishes a 12-Month Evaluation Framework for ScleroSafe® and a Potential Pathway to Long-Term Distribution

VANCOUVER, BC, Oct. 22, 2026 /CNW/ -- VVT Med Inc. (TSXV: VVTM) ("VVT Med" or the "Company"), a developer of minimally invasive, non-thermal, non-tumescent ("NT-NT") solutions for venous disease, today announced a definitive 12-month Trial Distribution and Evaluation Agreement (the "Agreement"), starting October 5^th, 2026, with Ebtec ("Ebtec"), a Panama-based distributor, to evaluate the market and clinical potential of ScleroSafe® in Panama. Publication of this announcement is subject to confirmation of execution by both parties.

Under the Agreement, Ebtec is appointed as importer and conditionally exclusive trial distributor of ScleroSafe® in Panama, subject to training, regulatory compliance, and purchase obligations. The Agreement provides for an initial order of at least ten ScleroSafe® Full Sets within 14 days of its effective date and an additional order of at least ten sets within six months. The parties intend to evaluate market demand, clinical use, customer development, and distributor performance during the trial period.

The Panama initiative represents another step in VVT Med's efforts to establish a broader commercial footprint in Latin America. It follows the Company's previously announced commercial agreement in the Dominican Republic and supports its strategy of developing local partnerships to facilitate physician education, clinical evaluation, and market access across the region. The agreement does not itself establish commercial adoption or regulatory clearance in Panama.

The Agreement provides for a review of distributor performance before the end of the 12-month trial period. Subject to satisfactory performance and mutual agreement, the parties may negotiate a separate five-year exclusive distribution agreement. No such long-term agreement has been executed, and there is no assurance that one will be reached.

"Panama represents an additional opportunity to build our presence in Latin America through a structured, locally supported evaluation of ScleroSafe," said Erez Tetro, Chief Executive Officer of VVT Med. "Following our commercial activities in the Dominican Republic, this agreement reflects our approach of working with regional partners to assess market needs, support physician training, and establish a foundation for potential longer-term commercialization."

The Company continues to pursue a measured international commercialization strategy, combining local distributor relationships with physician engagement and appropriate regulatory and clinical processes. Activities in Panama remain subject to the requirements of the trial agreement and applicable local regulations.

About VVT Med Inc. (VVTM)
VVT Medical develops, manufactures, and distributes minimally invasive, non-thermal, non-tumescent (NT-NT) solutions for the treatment of vein diseases, starting with varicose veins. VVT is one of the few FDA-cleared, standalone companies offering NT-NT varicose vein treatment technology. VVT's FDA-cleared and CE-marked catheter-based technologies, ScleroSafe® and V-Block™, enable safe, office-based procedures with no anesthesia, no downtime, and minimal pain and side effects. Addressing the widest range of vein diameters, VVT's solutions empower patients by treating both the medical and aesthetic aspects of vein disease, while enabling physicians to deliver effective, efficient, and cost-saving treatments through proprietary, simultaneous sclerosant injection and blood aspiration. The Company's patented technology portfolio includes 55 patents from 14 patent families across 20 countries, providing broad global intellectual property protection through 2038. For more information, visit www.vvtmed.com.

About Ebtec
Ebtec is a Panama-based business led by David Brunschtein, Chief Executive Officer. Under the Agreement, Ebtec is responsible for the importation and trial distribution of ScleroSafe® products in Panama, including applicable local regulatory and quality requirements. For more information, visit www.ebtec.net.

Cautionary Note Regarding Forward-Looking Statements
This news release contains statements that constitute "forward-looking statements" or "forward-looking information" (collectively, "forward-looking information") under applicable securities laws. Such forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the Company's actual results, performance or achievements, or developments to differ materially from those anticipated in such statements. Forward-looking information in this news release includes, but is not limited to, statements regarding the proposed trial distribution activities in Panama, anticipated training and evaluation activities, potential market adoption, the possibility of a subsequent five-year distribution agreement, and the Company's Latin American expansion strategy. Such statements reflect the current views of the Company and are not guarantees of future performance. They are based on assumptions including execution of the Agreement by both parties, completion of required training, satisfaction of local regulatory requirements, the distributor's performance, and the Company's ability to execute its business strategy and maintain its listing on the TSX Venture Exchange. Forward-looking information is subject to risks and uncertainties including: (a) failure to complete or maintain the Agreement; (b) failure to obtain necessary regulatory permissions or complete training; (c) failure to meet purchase or evaluation obligations; (d) limited physician adoption or unfavorable market conditions; (e) the possibility that no long-term agreement will be executed; and (f) financing requirements and market volatility. Actual results may differ materially. Readers are cautioned not to place undue reliance on such information. The Company undertakes no obligation to update or revise any forward-looking statements except as required by applicable law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE VVT Med Inc.